Literature DB >> 16098362

Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.

Takahiro Inoue1, Takehiko Segawa, Taizou Shiraishi, Toru Yoshida, Yoshinobu Toda, Tomomi Yamada, Naoko Kinukawa, Hidefumi Kinoshita, Toshiyuki Kamoto, Osamu Ogawa.   

Abstract

OBJECTIVES: To evaluate multiple known prognostic markers in localized prostate cancer using tissue microarrays in Japanese patients. Molecular studies have suggested that ethnicity influences prostate tumor biology.
METHODS: Specimens were studied from 52 patients who underwent radical surgery at our institution between 1997 and 2001 without neoadjuvant hormonal therapy and with three or more available and complete cancer spots. Ki67, p53, and androgen receptor antigen expression were examined. Immunohistochemical scores were compared with outcomes of chemical relapse as monitored using prostate-specific antigen.
RESULTS: Pathologic tumor classification (P = 0.047), World Health Organization score (P = 0.026), World Health Organization histologic grade (P = 0.026), and surgical margin status (P = 0.018) were significant conventional clinicopathologic variables for predicting biochemical failure. The tissue microarray Gleason sum (P = 0.038), tissue microarray primary Gleason grade (P = 0.013), Ki67 labeling index (P < 0.0001), p53 (P = 0.0097), and androgen receptor (P = 0.0113) antigen expression also were significant. Moreover, surgical margin status and Ki67 labeling index were independently associated with treatment failure.
CONCLUSIONS: Especially together, the Ki67 labeling index and p53 and androgen receptor expression in localized prostate cancer often predicted postoperative progression in Japanese patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098362     DOI: 10.1016/j.urology.2005.02.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  26 in total

1.  Endoglin suppresses human prostate cancer metastasis.

Authors:  Minalini Lakshman; Xiaoke Huang; Vijayalakshmi Ananthanarayanan; Borko Jovanovic; Yueqin Liu; Clarissa S Craft; Diana Romero; Calvin P H Vary; Raymond C Bergan
Journal:  Clin Exp Metastasis       Date:  2010-10-28       Impact factor: 5.150

2.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors:  Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal:  World J Urol       Date:  2008-04-05       Impact factor: 4.226

3.  A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.

Authors:  Nai-Dong Xing; Sen-Tai Ding; Ryoichi Saito; Koji Nishizawa; Takashi Kobayashi; Takahiro Inoue; Shinya Oishi; Nobutaka Fujii; Jia-Jv Lv; Osamu Ogawa; Hiroyuki Nishiyama
Journal:  Asian J Androl       Date:  2011-02-07       Impact factor: 3.285

4.  Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo.

Authors:  Takashi Kobayashi; Takahiro Inoue; Yosuke Shimizu; Naoki Terada; Atsushi Maeno; Yoichiro Kajita; Toshinari Yamasaki; Tomomi Kamba; Yoshinobu Toda; Yoshiki Mikami; Tomomi Yamada; Toshiyuki Kamoto; Osamu Ogawa; Eijiro Nakamura
Journal:  Mol Endocrinol       Date:  2010-03-04

5.  Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.

Authors:  Romain Mathieu; Shahrokh F Shariat; Christian Seitz; Pierre I Karakiewicz; Harun Fajkovic; Maxine Sun; Yair Lotan; Douglas S Scherr; Ashutosh Tewari; Francesco Montorsi; Alberto Briganti; Morgan Rouprêt; Ilaria Lucca; Vitaly Margulis; Michael Rink; Luis A Kluth; Malte Rieken; Alexander Bachman; Evanguelos Xylinas; Brian D Robinson; Karim Bensalah; Markus Margreiter
Journal:  World J Urol       Date:  2014-10-26       Impact factor: 4.226

6.  Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.

Authors:  Maximilian Burger; Stefan Denzinger; Christine G Hammerschmied; Andrea Tannapfel; Ellen C Obermann; Wolf F Wieland; Arndt Hartmann; Robert Stoehr
Journal:  J Mol Med (Berl)       Date:  2006-08-03       Impact factor: 4.599

7.  Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens from Japanese men with bladder cancer.

Authors:  Toshifumi Kurahashi; Hideaki Miyake; Junya Furukawa; Masafumi Kumano; Atsushi Takenaka; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

8.  Overexpression of ETS-1 is associated with malignant biological features of prostate cancer.

Authors:  Bo Li; Yosuke Shimizu; Takashi Kobayashi; Naoki Terada; Koji Yoshimura; Tomomi Kamba; Yoshiki Mikami; Takahiro Inoue; Hiroyuki Nishiyama; Osamu Ogawa
Journal:  Asian J Androl       Date:  2012-10-15       Impact factor: 3.285

9.  Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.

Authors:  Joseph Nariculam; Alex Freeman; Simon Bott; Phillipa Munson; Noriko Cable; Nicola Brookman-Amissah; Magali Williamson; Roger S Kirby; John Masters; Mark Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

10.  Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.

Authors:  Agnieszka Krzyzanowska; Giuseppe Lippolis; Leszek Helczynski; Aseem Anand; Mari Peltola; Kim Pettersson; Hans Lilja; Anders Bjartell
Journal:  J Histochem Cytochem       Date:  2016-03-29       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.